Synergistic effects of active specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer.
Sewall Wright strain 2 guinea pigs bearing pulmonary metastases of the syngeneic line 10 (L10) hepatocarcinoma were treated with a vaccine composed of 10(7) bacillus Calmette-Guérin admixed with 10(7) x-irradiated L10 tumor cells beginning 10 days after tumor inoculation. Although this treatment failed to cure most of the guinea pigs of their metastatic disease, histologic examination of the pulmonary tumors in the vaccinated guinea pigs provided evidence of a cell-mediated hypersensitivity response that disrupted the normally compact architecture seen in control tumors. When a monoclonal antibody against the L10 tumor was injected i.v. to evaluate the vascular permeability of the tumors, significantly more antibody localized in tumors of vaccinated guinea pigs than in tumors of untreated controls. These results suggested that blood-borne substances could be delivered more efficiently to L10 metastases after the tumor-bearing guinea pigs had been treated with vaccine. To determine whether such increased vascular permeability would enhance the antitumor effects of chemotherapeutic agents, combined immunotherapy and chemotherapy studies were performed. Although cyclophosphamide treatment by itself did not cure L10-bearing guinea pigs, cyclophosphamide used in conjunction with prior immunotherapy increased the survival rate of animals to more than twice that of animals treated with immunotherapy alone (74 vs 33%). These results suggest that one mechanism by which active specific immunotherapy enhances chemotherapy of disseminated tumors is by rendering tumor foci more permeable to subsequently administered cytotoxic drugs.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000628:therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D006168:Guinea Pigs; D007121:Immunocompetence / Q000187:drug effects; D007167:Immunotherapy; D008113:Liver Neoplasms; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000628:therapy
D000911:Antibodies, Monoclonal; D001500:BCG Vaccine; D003520:Cyclophosphamide